Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce - Scorecard - MDSpire
Advertisement
Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce
Clinical Scorecard: Comprehensive Review and Expert Recommendations on Long-acting Monoclonal Antibodies for Preventing Respiratory Syncytial Virus Infection: Insights from the ARMADA Taskforce
At a Glance
Category
Detail
Condition
Respiratory Syncytial Virus (RSV) infection in infants and young children
Key Mechanisms
Long-acting monoclonal antibodies (LAmAbs) provide passive immunization to prevent RSV disease
Target Population
Infants aged <8 months without maternal RSV vaccination, preterm infants (<37 weeks’ gestational age) aged <12 months, and children <24 months with high-risk conditions
Care Setting
Pediatric outpatient and inpatient settings globally, including low- and middle-income countries
Key Highlights
LAmAbs are highly efficacious and effective at preventing RSV disease and well tolerated across diverse populations.
Seasonal administration of LAmAbs is recommended, with local adaptation for year-round use in RSV-endemic regions.
Global implementation of LAmAb programs is strongly endorsed to reduce RSV burden, with emphasis on equitable access and affordability.
Guideline-Based Recommendations
Diagnosis
Identify infants and young children at risk of severe RSV disease based on age, gestational age, and presence of high-risk conditions.
Management
Administer LAmAbs to all infants <8 months old without maternal RSV vaccination at the start or during RSV season.
Provide LAmAbs to preterm infants (<37 weeks’ gestational age) aged <12 months.
Treat children <24 months with high-risk conditions (e.g., chronic lung disease, congenital heart disease) with LAmAbs.
Adapt administration timing seasonally or year-round based on local RSV epidemiology.
Monitoring & Follow-up
Conduct postimplementation surveillance for RSV disease through 2 years of age.
Monitor long-term respiratory outcomes and non-RSV infections in children receiving LAmAbs.
Risks
Consider affordability and access challenges, especially in low- and middle-income countries.
Evaluate concurrent use with maternal RSV vaccination as evidence evolves.
Patient & Prescribing Data
Infants and young children including term, preterm, and those with high-risk medical conditions
LAmAbs demonstrate high efficacy, effectiveness, and cost-effectiveness at preventing RSV disease; affordability is critical for implementation in LMICs.
Clinical Best Practices
Use evidence-based criteria to identify eligible infants and children for LAmAb prophylaxis.
Implement seasonal LAmAb administration aligned with local RSV epidemiology.
Promote equitable access to LAmAbs globally, prioritizing affordability in resource-limited settings.
Engage stakeholders and public health programs to support widespread LAmAb deployment.
Support ongoing research on LAmAb effectiveness in special populations and long-term outcomes.
by Paolo Manzoni, Eugenio Baraldi, Fabio Midulla, Olivier Claris, Sandro Dessardo, Terho Heikkinen, Richard Thwaites, Bosco Paes, Xavier Carbonell-Estrany, Dmytro Dobryanskyy, Merih Cetinkaya, Adel S Al Harbi, Ji-Man Kang, Anne Goh Eng Neo, Hsin Chi, Guilherme Sant’Anna, Mónica Villa Guillén, Gonzalo Luis Mariani, Marco Aurelio Palazzi Safadi, Soledad Urzua, Heather J Zar, Pierre Goussard, Barry Rodgers-Gray, Nicola Waghorne, Manuel Sanchez Luna
Study found species-specific differences in biofilm -forming capacity and antimicrobial susceptibility among supragingival bacterial isolates from patients with active dental caries.
